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Abstract
Background: Adherence has recently been suggested to be divided into these two components:
persistence (i.e., whether patients continue treatment or not) and compliance (i.e., whether
patients take doses as instructed). However, no study has yet assessed these two clinically relevant
components at the same time in adherence to antidepressant treatment in the clinical outpatient
setting.
Methods:  In this retrospective chart-review, 6-month adherence to antidepressants was
examined in 367 outpatients with a major depressive disorder (ICD-10) (170 males; mean ± SD
age 37.6 ± 13.9 years), who started antidepressant treatment from April 2006 through March 2007.
Additionally, we evaluated Medication Possession Rate (MPR), defined as the total days a
medication was dispensed to patients divided by the treatment period.
Results: Only 161 patients (44.3%) continued antidepressant treatment for 6 months. Among 252
patients who discontinued their initial antidepressant, 63.1% of these patients did so without
consulting their physicians. Sertraline use was associated with a higher persistence rate at month 6
(odds ratio 2.59 in comparison with sulpiride), and the use of anxiolytic benzodiazepines had a
positive effect on persistence to antidepressant treatment only at month 1 (odds ratio 2.14). An
overall MPR was 0.77; 55.6% of patients were considered compliant (i.e., a MPR of ≥ 0.8).
Conclusion:  Given a high rate of antidepressant discontinuation without consulting their
physicians, closer communication between patients and their physicians should be encouraged.
Although the use of anxiolytic benzodiazepines was associated with a higher persistence to
antidepressant treatment at month 1, the use of these drugs should be avoided as a rule, given their
well-known serious adverse effects.
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Background
While antidepressants have played an important role in
the treatment of depression, good adherence to medica-
tions is prerequisite to maintain those therapeutic bene-
fits. Despite this self-evident fact, the available evidence
has generally shown low adherence rates to antidepres-
sant treatment in patients with a major depressive disor-
der [1-3]. For example, the adherence rate was found to be
51% at week 16 and further dropped to 21% at week 33
in a sample of 4,312 privately insured outpatients in the
US [1]. Similarly, the Vantaa Depression Study showed a
one-year continuation rate as low as 50% in Finland (n =
269) [3]. Moreover, Hunot et al. conducted a 6-month
prospective study (n = 147) and found that less than half
the patients continued use of antidepressant for the 6
months, and only 19% of patients took antidepressants in
accordance with clinical guidelines over the study period
[4].
It is common to encounter patients who regularly come to
see their physicians but do not always take their medica-
tions as instructed. To take this fact into consideration,
adherence has recently been suggested to be divided into
these two components: persistence and compliance [5]. Per-
sistence is defined as continuously refilling prescriptions
in accordance with the suggested duration of the therapy,
which is determined by evaluating solely if the patient
continues treatment or not [5]. Compliance is the extent
in accordance with prescribed dosage and schedule, which
can be assessed with Medication Possession Rate (MPR)
(i.e., total days a medication was actually dispensed to
patients divided by treatment period in days). These two
components represent different aspects of patients' behav-
iours and should be separately assessed, which has been
reflected in recent studies in other physical and psychiatric
diseases [6,7], including schizophrenia [5] and bipolar
disorder [8]. However, surprisingly, there is only one
report that has assessed these two components in antide-
pressant treatment [9]. This study found a MPR of 80%
and a 6-month persistence rate of 65.9% in 85 patients
with a major depressive disorder who were treated with
either fluoxetine or paroxetine in a double-blind, rand-
omized clinical trial. However, these high values would
not be expected to thoroughly reflect our daily clinical
practice, given that participants in clinical antidepressant
trials are more highly motivated and encouraged to
receive treatment. Indeed, participants in clinical trials
have been suggested to represent a minority of patients in
routine clinical practice in terms of psychopathology [10].
In addition, this study did not evaluate effects of clinical
characteristics and other antidepressant drugs on persist-
ence and compliance.
To thoroughly evaluate patients' behaviours in taking
medications and different profiles in adherence among
antidepressants, both persistence and compliance need to
be examined in the daily clinical setting. In addition, to
further improve our understanding of characteristics of
patients' attitudes towards antidepressant treatment, the
effects of demographic and clinical characteristics on the
persistence and compliance should be investigated, too.
For example, a relationship between gender and adher-
ence has not been demonstrated consistently in the litera-
ture [11-13]; moreover, any gender-effect specifically on
either persistence or compliance has not been investi-
gated. The lack of the data is also true for any aging effect.
This paucity of data emphasizes the need of investigations
to assess the potential factors associated with good or
poor adherence and compliance, which would be
expected to provide relevant information for more effec-
tive treatment intervention.
To address this gap in the literature, we conducted a sys-
tematic chart review and examined persistence and com-
pliance to antidepressant drugs in outpatients with a
major depressive disorder in psychiatric clinics in Tokyo,
Japan. We also tried to assess the effects of demographic
and clinical characteristics on the persistence and compli-
ance.
Methods
Patient population
A retrospective chart review was conducted at 3 outpatient
clinics: (a) Department of Psychiatry, Saiseikai Central
Hospital, Tokyo, Japan, (b) Asakadai Mental Clinic,
Saitama, Japan, and (c) Ohizumi Mental Clinic, Tokyo,
Japan. Patients who visited one of these participating clin-
ics for the first time between between April 1, 2006 and
March 31, 2007 were screened. Among them, outpatients
were included if they started to receive antidepressant
treatment, were diagnosed with a major depressive disor-
der (F32 or F33 according to the International Classifica-
tion of Diseases (ICD), 10th edition), and had not received
any psychotropic agents (i.e., antidepressants, mood sta-
bilizers, anxiolytics, and antipsychotics) within the past 6
months before staring antidepressant treatment. Patients
who had a past or current history of any concomitant
ICD-10 diagnosis or unstable physical conditions that
required treatment were excluded. The study was carried
out in accordance with the latest version of the Declara-
tion of Helsinki and approved by the institutional review
board at all participating sites and exempted from the
requirement for informed consent because the study
involved de-identified data acquired during routine care.
Study design
The collected information included age, gender, and psy-
chotropic medications dispensed for 6 months after their
first visit. Patients were divided into three age groups for
further comparisons, based on their age at the day of theirBMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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first visit: before age 40, between 40 and 59, and 60 and
older, respectively. Daily doses of antidepressants were
converted to imipramine equivalents (IMIE) where 100
IMIE mg corresponds to paroxetine 26.7 mg, sertraline
66.7 mg, fluvoxamine 100 mg, milnacipran 100 mg, and
sulpiride 200 mg, respectively [14]. Sulpiride has been
approved for the treatment of depression as an antidepres-
sant drug in Japan and has been shown to be frequently
prescribed [15].
One of the primary outcome measures was the persistence
rate to any and initial antidepressant treatments, respec-
tively, 1, 3, and 6 months after their first visit. If patients
did not show up for one or more months after their sched-
uled appointment, it was considered as treatment discon-
tinuation, which is conventional criteria [6,16]. If patients
were hospitalized, the date of admission was regarded as
that of termination of outpatient treatment. The other pri-
mary outcome measure was compliance to any and initial
antidepressant treatments, respectively, using a MPR
defined as total days a medication was actually dispensed
to patients divided by treatment days. For example, when
a patient receives a total of 60-day supply of antidepres-
sants until his/her last visit at day 91, the corresponding
MPR is calculated to be 0.66 (60/91). Likewise, when a
patient receives a total of 160-day supply of antidepres-
sants until his/her last visit at day 183, MPR is 0.87 (160/
183). A MPR of 0.8 or more was defined as being compli-
ant to prescribed antidepressant medications [5].
When their initial antidepressant was discontinued or
switched to another agent, whether patients had con-
sulted their physicians before quitting the drug or not was
recorded based on descriptions of charts. As an initial
step, we interpreted qualitative reporting in charts. Partic-
ipating sites were affiliated with the same academic insti-
tution (Keio University, Tokyo, Japan), and physicians
working for those participating sites had been educated to
recorded reasons of medication change. Where descrip-
tions in charts were insufficient, physicians-of-record were
requested to provide additional information.
Data analysis
Statistical analyses were carried out using the Statistical
Package for Social Science (SPSS) version 16.0 for Win-
dows (SPSS Inc., Chicago). Prescribed doses of antidepres-
sants were compared among antidepressants, using an
analysis of variance (ANOVA). Logistic regression analysis
was also employed to examine predictors of persistence to
any antidepressant drug among age group, gender, and
the concomitant prescription of benzodiazepine-deriva-
tive anxiolytic or hypnotic at a previous survey point. In
order to assess predictors of persistence to an initial anti-
depressant drug, another logistic regression analysis was
employed, using those variables described in the previous
model as well as an antidepressant drug prescribed on
their first visit. A univariate general linear model was used
to examine the effects of age group, gender, the use of ben-
zodiazepine-derivative anxiolytic or hypnotic on the MPR
of any antidepressant medication. Another univariate
general linear model was generated to assess the effects of
those variables as well as a first antidepressant drug on the
MPR of the initial antidepressant. These general linear
models (fixed-effects model) were generated with main
effects and all interaction terms. When appropriate, we
also examined group differences with pairwise compari-
sons using the Tukey-Kramer HSD (honestly significant
difference). A p-value of < 0.05 was considered statisti-
cally significant and all tests were two-tailed.
Results
Description of the sample
A total of 2,756 patients that had newly visited one of the
participating sites during the targeted period were identi-
fied; of these, 1,365 patients were diagnosed with a major
depressive disorder. Among them, 998 patients had a
prior history of treatment with psychotropic agents within
the past 6 months or did not receive antidepressant treat-
ment on the day of their first visit. Charts of the remaining
367 patients were examined. Out of the target sample, the
mean ± SD age was 37.6 ± 13.9 years (range, 16 to 82
years), and 46.3% (n = 170) were men. There were no
missing data for statistical analyses.
Initial antidepressant treatment
Sulpiride was the most frequently prescribed antidepres-
sant (40.3%, n = 148), followed by paroxetine (31.1%, n
= 114), fluvoxamine (9.3%, n = 34), sertraline (9.0%, n =
33), milnacipran (8.4%, n = 31), amoxapine (1.4%, n =
5), and trazodone (0.5%, n = 2). The mean ± SD starting
dose of antidepressants was 54.8 ± 21.1 IMIE mg/day. Sig-
nificant differences in the initial dose were found among
antidepressants (F(6,360) = 7.241, p < 0.001); sertraline
(40.5 ± 9.9 IMIE mg/day) was lower in relative dose than
sulpiride (53.0 ± 23.7 IMIE mg/day, p = 0.03) and parox-
etine (62.0 ± 20.0 IMIE mg/day, p = 0.007). Benzodi-
azepine-derivative anxiolytics and hypnotics were
concomitantly prescribed at 33.2% and 48.0%, respec-
tively. There were no differences in benzodiazepine pre-
scription among antidepressants.
Persistence rates
The ratios of patients who continued an antidepressant
treatment are summarized in Tables 1 and 2. The persist-
ence rate to any antidepressant was more than 70% one
month after their first visit and gradually declined to
slightly less than half at month 6. Two thirds of the
patients continued to take their initial antidepressant
medication at month 1, and the rate dropped to approxi-
mately one third at month 6. Among 252 patients whoBMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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Table 1: Persistence Rates and Clinical Characteristics
Persistence Rate (%)
Baseline Month 1 Month 3 Month 6
Any antidepressant (n = 367) 72.8 54.0 44.3
Initial antidepressant 66.1 43.3 31.3
Sulpiride (n = 148) 70.9 48.6 35.1
Paroxetine (n = 114) 58.8 36.0 28.1
Fluvoxamine (n = 34) 60.6 29.4 20.6
Sertraline (n = 33) 75.8 51.5 51.5a
Milnacipran (n = 31) 67.7 51.6 19.4
Amoxapine (n = 5) 80.0 60.0 20.0
Trazodone (n = 2) 0.0 0.0 0.0
Persistence Rate to Any Antidepressant (%)
Sex
Female (n = 197) 64.4 49.2 40.6
Male (n = 170) 82.3 b 59.4 47.6
Age groups
Before age 40 (n = 241) 72.6 50.6 41.7
40–59 (n = 95) 75.8 61.1 44.2
60 or older (n = 31) 64.5 58.1 58.1
Anxiolytics use
No (n = 245) 68.2 51.8 41.6
Yes (n = 122) 82.0 c 58.2 48.4
Hypnotics use
No (n = 191) 70.2 50.1 40.8
Yes (n = 176) 75.6 49.7 47.2
a Logistic regression analysis found that sertraline use was associated with persistence to an initial antidepressant at month 6 (odds ratio = 2.59 in 
comparison with sulpiride, 95% CI = 1.16–5.77, p = 0.020).
b Male gender was associated with persistence to any antidepressant drug at month 1 (odds ratio = 2.37, 95% CI = 1.44–3.90, p = 0.001)
c The use of benzodiazepine-derivative anxiolytics also had a positive effect on the persistence to any antidepressant at month 1 (odds ratio = 2.14, 
95% CI = 1.22–3.73, p = 0.008).BMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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Table 2: Clinical Characteristics Associated with Higher Persistence
Odds Ratio (95% CI; p value)
Persistence to Initial Antidepressant
Month 1 a Month 3 b Month 6 c
Sulpiride (n = 148) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Paroxetine (n = 114) 0.60
(0.34–1.06; p = 0.08)
0.61
(0.36–1.04; p = 0.07)
0.76
(0.43–1.34; p = 0.35)
Fluvoxamine (n = 34) 0.80
(0.35–1.82; p = 0.59)
0.49
(0.21–1.12; p = 0.09)
0.59
(0.23–1.49; p = 0.27)
Sertraline (n = 33) 1.68
(0.67–4.18; p = 0.27)
1.32
(0.60–2.91; p = 0.49)
2.59 
(1.16–5.77; p = 0.02)
Milnacipran (n = 31) 1.13
(0.47–2.71; p = 0.78)
1.40
(0.63–3.13; p = 0.41)
0.56
(0.21–1.49; p = 0.25)
Amoxapine (n = 5) 0.00
(0.0-0.0; p = 0.99)
0.00
(0.0-0.0; p = 0.99)
0.00
(0.0-0.0; p = 0.99)
Trazodone (n = 2) 1.13
(0.12–11.1; p = 0.92)
1.13
(0.18–7.35; p = 0.90)
0.33
(0.03–3.28; p = 0.35)
Persistence to Any Antidepressant
Month 1d Month 3 e Month 6 f
Sex
Female (n = 197) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male (n = 170) 2.37
(1.44–3.90; p = 0.001)
1.42
(0.93–2.17; p = 0.10)
1.29
(0.84–1.97; p = 0.24)
Age groups
Before age 40 (n = 241) 1.00 (reference) 1.00 (reference) 1.00 (reference)
40–59 (n = 95) 1.01
(0.57–1.79; p = 0.97)
1.43
(0.87–2.33; p = 0.16)
1.02
(0.62–1.66; p = 0.95)BMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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discontinued their initial antidepressant, 63.1% (n = 159)
did so by their own decision without any consultation
with their physicians.
Odds ratios of significant variables are also summarized
in Tables 1 and 2. The use of benzodiazepine-derivative
anxiolytics was associated with a higher persistence rate to
any antidepressant at month 1, but not thereafter. The use
of sertraline had a positive effect on persistence to an ini-
tial antidepressant drug at month 6 as compared to sulpir-
ide while other antidepressants failed to show a
difference. Males and patients aged ≥ 60 were associated
with higher persistence rates to an initial antidepressant
drug at month 6 although they failed to show significant
effects on 6-month persistence to any antidepressant treat-
ment.
Medication possession rates
Results of MPRs were summarized in Tables 3 and 4.
Although the mean MPR of any antidepressant drug was
less than 0.8, 55.6% of patients were considered compli-
ant (i.e., showing a MPR of 0.8 or more). MPRs of the five
frequently prescribed drugs were similar to each other
without a group difference (Table 3). Univariate general
linear models found that gender and age group had signif-
icant effects on the MPR of any antidepressant, but failed
to find variables that have significant effects on the MPR
of an initial antidepressant.
Discussion
We conducted the first study that investigates persistence
and compliance to antidepressants in patients with a
major depressive disorder in the clinical outpatient set-
ting. Notwithstanding the limitations imposed by the ret-
rospective design as discussed below, the finding of low
persistence and insufficient compliance to antidepres-
sants in this study suggests that patients with depression
should be encouraged more to derive the full benefits
from their antidepressant treatment. In addition, males
were associated with a higher persistence and better com-
pliance rate to antidepressant treatment. A significant
association was also found between the use of benzodi-
azepine-derivative anxiolytics and a higher persistence
rate in the beginning of the treatment. While a causal attri-
bution cannot be made in light of the retrospective nature
of this study, the results highlight the critical importance
of devising effective treatment strategies to enhance
patients' adherence to medications in patients with
depression.
The overall persistence rate at month 6 was found to be as
low as 44% in the present study, which is comparable to
42–51% reported in previous surveys that were conducted
60 or older (n = 31) 0.70
(0.31–1.59; p = 0.40)
1.38
(0.65–2.96; p = 0.41)
1.96
(0.91–4.21; p = 0.08)
Anxiolytics use
No (n = 245) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes (n = 122) 2.14
(1.22–3.73, p = 0.008)
1.30
(0.82–2.04, p = 0.27)
1.38
(0.87–2.17, p = 0.17)
Hypnotics use
No (n = 191) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes (n = 176) 1.44
(0.88–2.36, p = 0.15)
1.24
(0.81–1.90, p = 0.33)
1.35
(0.87–2.17, p = 0.17)
Underlined figures represent statistically significant values.
a Model statistics: χ2  [11] = 36.0 (p < 0.001); Nagelkerke R2 = 0.13
b Model statistics: χ2  [11] = 23.8 (p = 0.014); Nagelkerke R2 = 0.084
c Model statistics: χ2  [11] = 25.8 (p = 0.007); Nagelkerke R2 = 0.095
d Model statistics: χ2  [5] = 24.3 (p < 0.001); Nagelkerke R2 = 0.093
e Model statistics: χ2  [5] = 8.4 (p = 0.14); Nagelkerke R2 = 0.03
f Model statistics: χ2  [5] = 8.0 (p = 0.16); Nagelkerke R2 = 0.03
Table 2: Clinical Characteristics Associated with Higher Persistence (Continued)BMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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in clinical settings [1-3]. Also, persistence rates to initial
antidepressants were similar to those in the literature (20–
40%) [17,18]. Besides these low persistence rates, another
concern is an insufficient compliance to antidepressants,
as slightly more than half the patients were considered
compliant. Poor compliance has been a major obstacle,
especially in the treatment of chronic disease; indeed, low
rates of compliant patients have been reported in chronic
physical illnesses, including hypertension (50–65%) [6,7]
and osteoporosis (53%) [16]. Given that major depressive
disorders frequently need a long-term antidepressant
treatment for relapse prevention [19,20], these illnesses
should be regarded as another chronic condition. Not-
withstanding this, the rate of compliant patients in this
study (56%) is lower than in schizophrenia (79%) [5] and
epilepsy (74%) [21] for which compliance to the medica-
tion has been more seriously considered and targeted.
These findings point to a necessity of targeting the medi-
cation adherence in depression more thoroughly than we
currently do.
Another important finding is more than 60% of dropouts
discontinued their initial antidepressant treatment with-
out consulting with their physicians. This high rate may
suggest insufficient communication between patients and
Table 3: Medication Possession Rates (MPR) and Clinical 
Characteristics
MPR (mean ± SD)
Any antidepressant (n = 367) 0.77 ± 0.28
Initial antidepressant 0.71 ± 0.31
Sulpiride (n = 148) 0.72 ± 0.28
Paroxetine (n = 114) 0.70 ± 0.35
Fluvoxamine(n = 34) 0.64 ± 0.30
Sertraline(n = 33) 0.77 ± 0.28
Milnacipran(n = 31) 0.78 ± 0.30
Amoxapine (n = 5) 0.64 ± 0.27
Trazodone (n = 2) 0.68 ± 0.64
MPR of any antidepressant
Sex a
Female (n = 197) 0.73 ± 0.29
Male (n = 170) 0.81 ± 0.26
Age group b
Before age 40 (n = 241) 0.76 ± 0.28
40–59 (n = 95) 0.76 ± 0.25
60 or older(n = 31) 0.87 ± 0.29
Anxiolytics use
No (n = 245) 0.77 ± 0.29
Yes (n = 122) 0.77 ± 0.25
Hypnotics use
No (n = 191) 0.78 ± 0.29
Yes (n = 176) 0.76 ± 0.27
aUnivariate general linear model found that gender had significant 
effects on the MPR (F(1,343) = 4.43; Corrected Model: F(23,343) = 1.78, p 
= 0.016, R2 = 0.11).
b Univariate general linear model found that age group had significant 
effects on the MPR (F(2,343) = 3.39, p = 0.035; Corrected Model: 
F(23,343) = 1.78, p = 0.016, R2 = 0.11).
Table 4: Effects of Clinical Characteristics on Medication 
Possession Rates (MPR)
F value P value
Effects on MPR of initial antidepressanta
Antidepressant F(6,279) = 0.87 0.52
Sex F(1,279) = 0.79 0.38
Age group F(2,279) = 3.36 0.036 b
Anxiolytics use F(1,279) = 0.88 0.35
Hypnotics use F(1,279) = 0.08 0.77
Effects on MPR of any antidepressantc
Sex F(1,343) = 4.43 0.036
Age group F(2,343) = 3.39 0.035
Anxiolytics use F(1,343) = 1.24 0.27
Hypnotics use F(1,343) = 0.075 0.78
Underlined figures represent statistically significant values.
aUnivariate general linear model, Corrected Model: F(87,279) = 1.29, p = 
0.07, R2 = 0.29
bAlthough the p-value was < 0.05, the model statistics failed to show 
any statistical significance as described above.
cUnivariate general linear model, Corrected Model: F(23,343) = 1.78, p 
= 0.016, R2 = 0.11BMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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their physicians. One interesting survey, including tele-
phone interviews in 401 patients with depression and
written surveys in 137 prescribing physicians, showed that
72% of physicians reported that they usually asked
patients to continue using antidepressants for at least 6
months, but only 34% of patients reported that their phy-
sicians educated them to continue using antidepressants
for this duration and 56% reported receiving no instruc-
tions [22]. Further, patients who said they were told to
take their medication for less than 6 months were 3 times
more likely to discontinue therapy, as compared with
patients who said they were told to continue therapy
longer. The percentage of 60% that we found in our study
could have been reduced, to some extent, with appropri-
ate instructions to patients. Elwyn et al. suggested that the
involvement of patients in shared decision making is one
of the key components of enhancing adherence [23].
Combined with the findings of those previous studies
[22,24], our results emphasize the need of a much closer
liaison between patients and their physicians.
A positive effect of the use of benzodiazepine-derivative
anxiolytics on the persistence to antidepressant treatment
was found at month 1. Although benzodiazepines them-
selves have little or no antidepressant effect, their anxio-
lytic and hypnotic effects could diminish associated
symptoms such as anxiety and insomnia before antide-
pressants start to exert their effects, which in turn may
result in better persistence to the treatment. In fact, Furu-
kawa et al. reported that patients treated with combina-
tion therapy with a benzodiazepine were 37% less likely
to dropout than with an antidepressant alone [25]. How-
ever, the benefits of benzodiazepines seem to be lost
beyond one month as no significant effect was observed at
months 3 and 6. Physicians should also keep in mind that
adverse effects of benzodiazepines are potentially very
serious. Benzodiazepines have been reported to impair
cognitive function, including memory [26], and to be
associated with dependence [27]. Further, they increase
the risk of falls [28], which may well be associated with a
high mortality rate in the elderly. Considering an absolute
difference in the 1-month persistence rate as low as 14
points in percentage between benzodiazepine users and
non-users, the benefit of using this drug may be limited.
Given those serious side effects and limited potential ben-
efits, the use of benzodiazepines should not be justified as
a rule.
We also found that the use of sertraline might predict a
long-term persistence to antidepressant treatment. Given
that persistence rates or time to discontinuation could be
utilized as a relevant outcome measure as recent large-
scaled clinical trials do [29,30], sertraline may be a good
first-line antidepressant drug in the treatment of depres-
sion. Poorer efficacy and a higher frequency of side effects
are known to be linked to a lower persistence rate in the
treatment with antidepressants [31]. A reported better side
effect profile in sertraline [11] may contribute to our find-
ing. However, these preliminary results should be inter-
preted with caution since we did not directly evaluate
therapeutic and adverse effects of these medications in
this study. In fact, the finding of varying persistence rates
across medications could reflect confounding by the pro-
vider effect, and sertraline is the newest antidepressant
that became available in 2006 in Japan. We cannot deny a
possibility that physicians might have titrated the dose of
this newer drug more carefully than the other older drugs,
resulting in the higher persistence to sertaline that we
observed. The fact that the initial dose of sertraline was
lower than that of sulpiride may support this notion. In
addition, although patients who had received psycho-
tropic drugs within the past 6 months were excluded from
this survey, we cannot reject a possibility that some of the
patients had received prior antidepressant treatment in
their previous episodes, if any, which might have affected
the outcomes. Cost of medications is also expected to
affect persistence to antidepressant treatment in many
clinical settings. However, this is unlikely the case in the
present study since at least 70% of medication fees are
covered by the national insurance system in Japan.
Males showed a higher persistence and better compliance
in this study; however, this relationship has not been con-
sistent in the literature [11-13]. Burra et al. reported that,
consistent with our study, male patients were more com-
pliant to prescribed medications than female patients in
80 patients in Canada [11]. On the other hand, male gen-
der was reported to be associated with a greater likelihood
of discontinuation in the US (n = 406) [12] and Belgium
(n = 66) [13]. These discrepant findings may be derived
from different social and cultural backgrounds. We also
found a higher persistence rate and MPR in older patients,
which is in line with more positive attitudes towards anti-
depressants in this population [3]. Older people's literally
compliant behaviours may explain this finding. However,
these potential causes of this gender difference in persist-
ence and compliance remain speculative and warrant fur-
ther investigations.
There are several limitations to be noted in this study.
First, the results in the present study should be interpreted
in light of the relatively small sample size. Second, infor-
mation on many clinical and demographic characteristics
was lacking. Moreover, as we used broad exclusion criteria
such as a past or current history of any concomitant ICD-
10 diagnosis or unstable physical conditions, the sample
collected in this study might not have been representative
of the entire general population with depression. Further-
more, behaviours towards treatment are expected to be
subject to patients' social and cultural backgrounds. TheseBMC Psychiatry 2009, 9:38 http://www.biomedcentral.com/1471-244X/9/38
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limitations indicate a necessity of further information
from various clinical settings in order to provide a robust
agreement on this issue. Third, patients were not rand-
omized to the antidepressants, and physicians' prescrib-
ing behaviours may reflect a bias in training and both
direct and indirect influence of current and local standard
of care [32]. Since different treatment sites may have an
impact on patients' behaviours towards antidepressant
treatment, we performed additional analyses, including
site as a parameter. Although we did not find any signifi-
cant effect of this factor on persistence rate or MPR, the
relationship between patients and their physicians is still
likely to affect treatment discontinuation. Fourth, treat-
ment discontinuation was defined as not showing up for
one or more months after their scheduled appointment.
Although this definition has conventionally been used in
this type of study [6,16], some patients might have contin-
ued treatment at another facility. Furthermore, refill pat-
terns do not directly measure compliance or even
persistence with certainty. Fifth, the retrospective nature
of this survey did not allow us to evaluate the effectiveness
of drug treatment, and treatment intervention was not
standardized. Most importantly, we do not have data on
actual clinical outcomes. Some of the patients who were
regarded as dropouts in the present study might have dis-
continued their treatment because of an improvement in
their illness although antidepressant treatment should be
continued for more than 6 months to prevent a relapse
[19,20,33]. Further, patients might not have taken their
medications even though they showed up for appoint-
ments. However, these limitations are not unique to our
study. Indeed, the key studies assessed patients' adherence
to medications retrospectively [5-7,21]. Despite this posi-
tive indication, our preliminary findings need to be repli-
cated in a larger number of samples, using a prospective
study design. Finally, an association between persistence
and compliance was not evaluated since these two out-
come measures were influenced by the same factor, sex.
Further invistigations are warranted to evaluate the inter-
action between these two measures, which will provide a
better understanding of patients' behaviours towards anti-
depressant treatment.
Conclusion
We examined persistence rates and MPRs in 367 patients
with a major depressive disorder. Low persistence and
poor compliance to antidepressant treatment were found
to be problematic in patients with depression in the clin-
ical outpatient setting. Porer compliance to medications
in patients with depression than in those with schizophre-
nia or epilepsy points to a necessity of targeting the med-
ication compliance in this chronic illness, too. Since there
is a high rate of antidepressant discontinuation without
any consultation with physicians, closer communication
between patients and their physicians should be encour-
aged, which in turn would be expected to enhance persist-
ence to medications and hence improve outcomes. The
use of sertraline may also enhance persistence to antide-
pressant treatment. Future prospective studies are war-
ranted to further address these preliminary findings.
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